The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales by Marteau, Dave et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1136/bmjopen-2015-007629
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Marteau, D., McDonald, R., & Patel, K. (2015). The relative risk of fatal poisoning by methadone or
buprenorphine within the wider population of England and Wales. BMJ open, 5(5), e007629.
https://doi.org/10.1136/bmjopen-2015-007629
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
The relative risk of fatal poisoning by
methadone or buprenorphine within the
wider population of England and Wales
Dave Marteau,1 Rebecca McDonald,2 Kamlesh Patel1
To cite: Marteau D,
McDonald R, Patel K. The
relative risk of fatal poisoning
by methadone or
buprenorphine within the
wider population of England
and Wales. BMJ Open
2015;5:e007629.
doi:10.1136/bmjopen-2015-
007629
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2015-007629).
Received 9 January 2015
Revised 30 March 2015
Accepted 9 April 2015
1Health and Human
Development, University of
East London, London, UK
2Addictions Department,
Institute of Psychiatry,
Psychology & Neuroscience,
King’s College London,
London, UK
Correspondence to
Dr Dave Marteau,
d.m.marteau@sa.uel.ac.uk
ABSTRACT
Objective: To examine the population-wide overdose
risk emerging from the prescription of methadone and
buprenorphine for opioid substitution treatment in
England and Wales.
Design: Retrospective administrative data study.
Setting: National databases for England and Wales.
Participants/cases: Drug-related mortality data were
drawn from the Office for National Statistics, and
prescription data for methadone and buprenorphine
were obtained from the National Health Service for the
years 2007–2012. During this 6-year period, a total of
2366 methadone-related deaths and 52 buprenorphine-
related deaths were registered, corresponding to
17 333 163 methadone and 2 602 374 buprenorphine
prescriptions issued. The analysis encompassed
poisoning deaths among members of the wider
population of England and Wales who consumed, but
were not prescribed these medications, in addition to
patients prescribed methadone or buprenorphine.
Main outcome measures: Mortality risk: substance-
specific overdose rate per 1000 prescriptions issued;
relative risk ratio of methadone in relation to
buprenorphine.
Results: During the years 2007–2012, the pooled
overdose death rate was 0.137/1000 prescriptions of
methadone, compared to 0.022/1000 prescriptions of
buprenorphine (including buprenorphine-naloxone).
The analysis generated a relative risk ratio of 6.23 (95%
CI 4.79 to 8.10) of methadone in relation to
buprenorphine. UK Borders Agency data were taken into
consideration and revealed that only negligible amounts
of methadone and buprenorphine were seized on
entering UK territory between 2007 and 2012,
suggesting domestic diversion.
Conclusions: Our analysis of the relative safety of
buprenorphine and methadone for opioid substitution
treatment reveals that buprenorphine is six times safer
than methadone with regard to overdose risk among the
general population. Clinicians should be aware of the
increased risk of prescribing methadone, and tighter
regulations are needed to prevent its diversion.
INTRODUCTION
Opioid use constitutes a global public
health problem, as heroin users experience
signiﬁcantly elevated mortality rates.1 In the
UK, heroin and other opioids are the main
contributor to drug-related deaths,2 despite a
much lower prevalence of use relative to
other illicit drugs (eg, cocaine).3
The UK National Health Service (NHS)
provides opioid-dependent users with access
to methadone and buprenorphine as substi-
tution therapy.4 Methadone is a synthetic
opioid receptor agonist, while buprenor-
phine is a mixed agonist-antagonist which is
prescribed as either a single-ingredient tablet
or in combined formulation with naloxone,
a potent opioid antagonist that is added to
deter patients from injection use.5
Opioid substitution treatment is the most
effective intervention for opioid depend-
ence.6 7 It has been found to reduce the risk
of drug-related death8–11 as well as the inci-
dence of criminal offending12 and is asso-
ciated with the relatively low HIV rate among
injection drug users in England and Wales.13
While many randomised controlled trials
have compared methadone and buprenor-
phine with regard to their effectiveness at
retaining people in treatment, suppressing
craving, and reducing illicit opioid use, less is
known about their relative safety. In a
Strengths and limitations of this study
▪ Study is the first relative risk study of methadone
versus buprenorphine in England and Wales, and
the second only national study globally.
▪ Study draws on a very large source of data,
comprising more than 19 million prescriptions
across 6 years.
▪ Study presents an evaluation of risk across a full
drug-using culture.
▪ Data do not allow the identification of differences
in severity of drug dependence between patients
prescribed methadone and those prescribed
buprenorphine.
▪ The data used are based on the number of pre-
scription items issued rather than number of
identified patients.
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meta-analysis of 31 trials, only two studies tested the
safety of methadone and buprenorphine, ﬁnding no sig-
niﬁcant difference in the rate of adverse events between
the treatment samples.7
Similarly, the question of the relative safety of metha-
done and buprenorphine in the wider community, that
is, among individuals not in receipt of a prescription
and consuming diverted drugs, has received fairly little
attention. This is surprising for at least two reasons: ﬁrst,
misuse of either drug can cause fatal overdose, particu-
lar when consumed in combination with other central
nervous system depressants;14–18 second, the diversion of
buprenorphine and particularly methadone to the illicit
market for sale or exchange is a known problem in the
UK and abroad.19 20
Recent attempts to address the problem of diversion
in the UK, by the introduction of supervised consump-
tion of buprenorphine and methadone at the dispens-
ing pharmacy,21 have led to a signiﬁcant reduction in
the rate of methadone deaths in relation to number of
patients treated.22 Nonetheless, it appears that the sub-
stantial majority of methadone overdoses occur in the
general population. The risk represented by black-
market methadone is illustrated by a UK-wide analysis of
methadone-related deaths between 2009 and 2012.23–26
Of the reported 1117 deaths that involved methadone
alone or in combination with other drugs, only 36%
occurred among individuals who were known to be
receiving methadone treatment. This ﬁnding is consist-
ent with previous reports from New South Wales
(Australia) and Germany,27 28 where at least half of
methadone overdose deaths were the result of diversion.
Over a 9-month period, the New South Wales study28
also compared total overdose mortality rates (ie,
in-treatment and diversion) related to buprenorphine
and methadone, and found that methadone was asso-
ciated with a fourfold risk of overdose.
To date, there has been only one published evaluation
of the relative safety of buprenorphine and methadone
in a national treatment setting. In a review of drug-related
deaths in France between 1994 and 1998, Auriacombe
et al29 found that in relation to the number of patients
receiving opioid substitution treatment, methadone was
at least three times more lethal than buprenorphine in
terms of overdose deaths among the French population
as a whole (ie, among patients and the general public).
In a follow-up study, Auriacombe et al30 noted that opiate
overdose deaths had declined substantially following the
introduction of buprenorphine treatment, but due to the
correlational nature of the data, causality cannot be
inferred.
To the best of our knowledge, this study constitutes
the ﬁrst effort to assess the relative safety of buprenor-
phine and methadone in Britain. Using Ofﬁce for
National Statistics mortality data and National Health
Service prescription data for England and Wales from
the years 2007 to 2012, the current study aimed to
examine the population-wide overdose risk emerging
from the prescription of methadone and buprenorphine
for opioid substitution treatment.
METHODOLOGY
Ethics committee approval
Following National Research Ethics Service guidance, ethics
committee approval was not sought for this study as all
analyses encompassed non-conﬁdential, non-attributable,
de-identiﬁed data available via public databases.
Identification of individual number of prescriptions
Total quantities of buprenorphine, buprenorphine-
naloxone and methadone dispensed in England and
Wales from 2007 to 2012 were drawn from two sources:
the National Health Service (England), and National
Health Service (Wales) Prescription Cost Analysis data
reports. To exclude prescriptions for either detoxiﬁca-
tion or pain management, sublingual formulations of
less than 2.0 mg of buprenorphine, and buprenorphine
patches were not counted. Methadone linctus, a prepar-
ation prescribed for coughs, was also excluded. As they
are prescribed almost exclusively for the treatment of
severe pain rather than substance dependence, metha-
done tablets were also disregarded. The use of metha-
done to manage pain is far less common than for
treatment drug dependence. For instance, in Wales, in
the years 2010/2011, methadone tablets comprised <1%
of all methadone prescriptions. This accords with a sep-
arate UK ﬁnding that 99.5% of methadone dispensed in
Scotland in 2008/2009 was against prescriptions for the
treatment of substance dependence.22
Buprenorphine and buprenorphine-naloxone prescrip-
tions are often dispensed as a composite of two or more
individual items. For example, a 10 mg prescription com-
prises one box of 8 mg tablets, and one box of 2 mg
tablets. Each of these boxes is recorded on the database as
an individual dispensed prescription, leading to double
counting. As a remedial means to determining the actual
number of patients treated with buprenorphine or
buprenorphine-naloxone, a survey was conducted of the
29 principal NHS treatment services in England and Wales
to establish mean daily doses prescribed to patients.
Fourteen services responded (48%). Accumulated returns
from the survey produced mean average doses of 10.6 mg
per day for buprenorphine substitution treatment (dose
range from 6.14 mg to 11.9 mg), and 9.3 mg per day for
buprenorphine-naloxone substitution treatment (dose
range from 6.0 mg to 10.55 mg). Across all the 6 years
studied, the mean average dose for all buprenorphine pre-
scriptions was 10.43 mg per day.
The average dose of methadone across the 6 years was
46.6 mg per day. The total quantities of each drug dis-
pensed per annum were subdivided by these doses to
yield the total numbers of individual prescriptions
written each year. As it is the standard duration of a sub-
stitution treatment prescription form raised in England
and Wales (FP10 MDA), all prescriptions of
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buprenorphine, buprenorphine-naloxone and metha-
done were presumed to be of 14 days’ duration.
Identification of number of buprenorphine and/or
methadone related deaths
Mortality data were drawn from the Ofﬁce for National
Statistics ‘Deaths Related to Drug Poisoning in England
and Wales’ 2012 data set.31 In calculating deaths related
to methadone or buprenorphine, the cause of death was
deﬁned using the WHO International Classiﬁcation of
Diseases, Tenth Revision (ICD-10) codes. Deaths were
included when the underlying cause was drug poisoning,
with buprenorphine and/or methadone mentioned on
the death certiﬁcate.
When both drugs were referenced on a death certiﬁ-
cate, the death was included in the breakdown of both
drugs. Deaths in England and Wales include non-
residents. Figures were based on deaths registered in
each calendar year.
Identification of imported quantities of methadone and
buprenorphine
To control for a potential confounding inﬂuence of
illegally imported quantities of these drugs, the study
incorporated UK Borders Agency data of Class A and
Class C drugs seized while entering UK territory
between 2006 and 2012.
Analysis
Causes of death and prescriptions issued to the user
were tabulated separately. These numbers were aggre-
gated to produce an estimate of the total fatalities and
prescriptions issued during the study period. A summary
measure ‘Buprenorphine-All’ was created for combined
prescriptions of buprenorphine and buprenorphine-
naloxone, as UK Ofﬁce for National Statistics mortality
records did not differentiate between these two
formulations.
To compare the risk of fatal overdose represented by
the two drugs, the total number of prescriptions for
buprenorphine (including buprenorphine-naloxone)
and methadone were divided by the number of fatal poi-
sonings attributed to either drug to calculate the com-
parative risk of fatal poisoning for the whole population
from use of either drug, expressed as a death rate per
1000 prescriptions.
Risk ratios and CI were calculated by means of stand-
ard formula using the open-source effect size calculator
by Wilson.32
RESULTS
There were 2366 deaths related to methadone poisoning
and 57 deaths related to buprenorphine in England and
Wales between 2007 and 2012 (see table 1).
Almost seven times more prescriptions were issued for
methadone than for buprenorphine between 2007 and
2012: 17.3 million prescriptions for methadone com-
pared to only 2.6 million for buprenorphine (including
buprenorphine-naloxone; see table 2). Over that time,
the proportion of buprenorphine (all) to methadone
prescriptions increased from 14% in 2007 to 18% in
2012, with methadone prescriptions gradually decreas-
ing, following a peak of 3.1 million prescriptions in
2010. By contrast, buprenorphine-naloxone and bupre-
norphine prescriptions continued to increase through-
out, with buprenorphine-naloxone increasing from 0.4%
of total prescriptions in 2007 to 2.6% in 2012 (ﬁgure 1).
Among the whole population of England and Wales,
there were 0.137 methadone-related deaths per 1000
prescriptions of methadone and 0.022 buprenorphine-
Table 1 Number of deaths related to drug poisoning where buprenorphine and/or methadone were mentioned on the death
certificate by cause, England and Wales, 2007–2012
2007 2008 2009 2010 2011 2012 Total
Methadone 325 378 408 355 486 414 2366
Accidental poisoning by drugs, medicaments and biological substances 149 202 242 215 427 342 1577
Assault by drugs, medicaments and biological substances 1 2 1 0 0 2 6
Intentional self-poisoning and poisoning of undetermined intent, by drugs,
medicaments and biological substances
42 32 26 42 48 47 237
Mental and behavioural disorders due to drug use (excluding alcohol
and tobacco)
133 142 139 98 11* 23 546
Buprenorphine 8 9 9 7 14 10 57
Accidental poisoning by drugs, medicaments and biological substances 2 4 8 5 12 8 31
Assault by drugs, medicaments and biological substances 0 0 0 0 0 0 0
Intentional self-poisoning and poisoning of undetermined intent, by drugs,
medicaments and biological substances
1 2 1 0 2 1 6
Mental and behavioural disorders due to drug use (excluding alcohol
and tobacco)
5 3 0 2 0 1 10
*In January 2011 the Office for National Statistics introduced a new version of ICD-10 (v2010), which featured stricter criteria for recording
under this category: http://www.ons.gov.uk/ons/rel/subnational-health3/deaths-related-to-drug-poisoning/2011/index.html.
Source: Office for National Statistics.
ICD-10, International Classification of Diseases, Tenth Revision.
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related deaths per 1000 prescriptions of buprenorphine-
based drugs for the substitution treatment of opioid
dependence (see table 3).
In terms of a fatality among the population of
England and Wales as a whole, methadone represented
a risk six times that of buprenorphine (RR 6.23; 95% CI
(4.79 to 8.10)) (ﬁgure 2).
Could the methadone or buprenorphine involved in these
deaths have come from other countries?
Changes in the way in which seizures are recorded by
the UK’s customs authority (the UK Borders Agency)
implies that no methadone data are available for years
2010/2011 and 2011/2012 (methadone seizures were
incorporated within the ‘Other class A’ return and
cannot be identiﬁed individually, see table 4). Reporting
in preceding years (2006/2007–2009/2010) indicates a
very low quantity of methadone entering into UK
territory.
According to UK Borders Agency reports, no buprenor-
phine was seized by UK customs in either 2006/2007 or
2007/2008.33 Buprenorphine was incorporated within the
‘Other class C’ returns from year 2008/2009; therefore, no
seizure data were available for the remaining period of this
study. In the 4 years that span 2006/2007 and 2009/2010
there were a total of 19 seizures of methadone by UK
customs. In none of these years did the total quantity of
methadone seized by the UK Border Agency amount to
1000 doses. The total number of doses of methadone
seized, therefore, amounted to less than 4000, while the
average annual number of methadone and buprenor-
phine doses prescribed in England and Wales, over the
same 4 year period (2006–2007 to 2009–2010), exceeded
38 million and 3.8 million doses, respectively. There have
been no reports of detection of any illegal manufacture of
methadone or buprenorphine in the UK throughout the
period of this study.33
DISCUSSION
Statement of principal findings
Dose for dose, methadone was found to present a signiﬁ-
cantly greater risk of fatal overdose to the wider popula-
tion than buprenorphine. Our ﬁnding is based on
national administrative data collected in England and
Wales between 2007 and 2012, and is consistent with the
only published national study of this type.29 Further, our
ﬁnding is supported by a study from New South Wales28
which reported a fourfold risk of overdose associated
with methadone relative to buprenorphine.
During the 6-year period analysed in the present
study, a very minor amount of imported methadone or
buprenorphine was seized by UK customs, representing
only a small fraction of prescriptions: per every dose
seized by UK customs, roughly 10 000 prescriptions for
methadone or buprenorphine were issued. Based on
this ratio, the authors assume that illicitly imported
methadone or buprenorphine were most likely not
involved in the overdose deaths studied.
Strengths and weaknesses of the study
The high number of people enrolled in opioid substi-
tute treatment in England and Wales during the 6-year
study period (approximately 766 000 patients) is consid-
erably larger than the sample of 140 140 cases analysed
in the French investigation by Auriacombe et al.29 This
allowed for a greater degree of conﬁdence in calculating
the relative risk (RR) of fatal overdose emerging from
methadone and buprenorphine use.
Moreover, customs data were taken into consideration
to control for illegal import of buprenorphine and
methadone into the UK.
Table 2 Prescriptions issued in England and Wales for opioid substitution treatment
Year Buprenorphine-naloxone Buprenorphine HCL Buprenorphine All Methadone
2007 12 295 344 703 356 998 2 513 076
2008 34 585 352 486 387 071 2 779 327
2009 64 736 371 327 436 063 3 017 531
2010 74 876 377 628 452 504 3 152 889
2011 79 215 387 357 466 572 3 025 956
2012 85 556 417 610 503 166 2 844 384
Total 351 263 2 251 111 2 602 374 17 333 163
HCL, hydrochloride.
Bold was used simply to indicate headings, sub-total and totals.
Figure 1 Total prescriptions issued in England and Wales
for opioid substitution treatment.
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The collation of data at the prescription item level
(rather than numbers of patients treated) meant that
the number of buprenorphine prescriptions had to be
calculated on the basis of mean doses. However, the
mean buprenorphine dose identiﬁed in this study
(10.43 mg per day) is broadly consistent with the pooled
average dose of 11.96 mg per day, as generated by seven
published ﬂexible-dose trials of buprenorphine with
doses ranging from 8.9 mg to 12.7 mg.34–40
Meaning of the study: possible explanations and
implications for clinicians and policymakers
The inclusion of UK customs data revealed that only neg-
ligible amounts of methadone and buprenorphine were
seized during the study period, implying that illicitly
imported methadone or buprenorphine are unlikely to
be risk factors for overdose in England and Wales.
This ﬁnding points to domestic diversion as the prob-
able source of black-market methadone and buprenor-
phine implicated in the overdose deaths of individuals
not in treatment.
Like other areas of medical research, the evaluation of
opioid substitution therapy has traditionally focused on
assessing the impact of treatment on clinical outcomes
within treatment cohorts. However, our ﬁndings suggest
that the degree of diversion of prescribed opioid
substitutes19 25 26 41 and associated overdose risk in the
wider population should also be taken into
consideration.
Neither methadone nor buprenorphine are free from
risk, not lastly because of potentially hazardous interac-
tions when taken together with other central nervous
system depressants (eg, benzodiazepines, alcohol),18 but
our results demonstrate that for the years 2007–2012
buprenorphine was signiﬁcantly safer for the popula-
tion of England and Wales.
In appraising the cost-effectiveness of the methadone
and buprenorphine, the National Institute for Health &
Care Excellence4 recommends that “[t]he decision about
which drug to use should be made on a case by case
basis, taking into account a number of factors, including
the person’s history of opioid dependence, their commit-
ment to a particular long-term management strategy, and
an estimate of the risks and beneﬁts of each treatment
made by the responsible clinician in consultation with
the person. If both drugs are equally suitable, methadone
should be prescribed as the ﬁrst choice”.
While taking full account of the limitations identiﬁed
in the preceding section, this study identiﬁes a substan-
tial RR differential between methadone and buprenor-
phine. Our ﬁnding, together with previous UK25 26 and
international reports27 28 30 of overdose fatalities linked
to methadone diversion, suggests that the treatment
sector may need to reappraise its relationship with
methadone.
Generally, opioid substitution treatment in the UK
begins under a regime of supervised consumption in a
community pharmacy, but weekend and bank holiday
closures mean that from the outset many patients are
trusted to take home up to 2 or 3 days’ prescription. UK
clinical guidelines42 suggest that supervised consump-
tion can be relaxed and take-home doses prescribed
when a doctor has good reason to believe that a patient
will be able to maintain compliance with his or her
methadone treatment.
The risk of methadone diversion into the black
market makes it apparent that this can be an extremely
difﬁcult judgement for a clinician to make regarding the
potential safety implications for persons other than the
individual patient.
Table 3 Methadone and buprenorphine-related death rate per 1000 prescriptions issued
Buprenorphine Methadone
Year Deaths per 1000 ℞ Deaths per 1000 ℞ Relative risk CI (95%)
2007 8 0.022 325 0.129 5.77 2.86 to 11.64
2008 9 0.023 378 0.136 5.85 3.02 to 11.33
2009 9 0.021 408 0.135 6.55 3.38 to 12.68
2010 7 0.015 355 0.113 7.28 3.44 to 15.38
2011 14 0.030 486 0.161 5.35 3.15 to 9.11
2012 10 0.020 414 0.146 7.32 3.91 to 13.71
Total 57 0.022 2366 0.137 6.23 4.79 to 8.10
℞=prescriptions.
Figure 2 Methadone and buprenorphine-related death rate
per 1000 prescriptions.
Marteau D, et al. BMJ Open 2015;5:e007629. doi:10.1136/bmjopen-2015-007629 5
Open Access
 o
n
 11 O
ctober 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2015-007629 on 29 May 2015. Downloaded from 
To conclude, for clinicians and policymakers alike,
both risk of diversion and the signiﬁcant RR differential
between methadone and buprenorphine, as identiﬁed
in this study, should form part of individual treatment
decisions as well as treatment guidelines.
Unanswered questions and future research
Buprenorphine-naloxone shows early promise of
increased safety over single-ingredient buprenorphine,43
but there are also indications that its self-injection can
represent a comparable risk of death to the single-agent
formulation.44 The short half-life of naloxone relative to
buprenorphine may mean that the intoxicating effect of
the buprenorphine is sometimes merely delayed rather
than eliminated following injected use.44 There are
insufﬁcient data within this evaluation to draw any con-
clusion on the question of the comparative safety of
buprenorphine-naloxone versus single-ingredient bupre-
norphine; this should be addressed by future studies.
An Australian study36 reported an indication of
increased risk of mortality among patients following the
cessation of buprenorphine treatment. Measurement of
mortality following the cessation of treatment by either
buprenorphine or methadone is beyond the scope of this
study and would be a valuable subject for future research.
The study could not establish if there were differences
in severity of dependence between the two patients
groups (ie, those prescribed methadone and those pre-
scribed buprenorphine). The feasibility of increasing
the use of buprenorphine over methadone in the pre-
scribed management of opioid dependence is, there-
fore, beyond the scope of this study.
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